shutterstock_1574432263_nitpicker-1-
25 February 2021AmericasMuireann Bolger

Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic

A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug (Carvedilol).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
12 October 2021   Teva Pharmaceuticals has once again petitioned the US Court of Appeals for the Federal Circuit to reconsider its decision in a dispute over generic drug labelling which held that the drugmaker infringed GlaxoSmithKline’s Coreg heart drug.
Big Pharma
11 October 2021   The English High Court has found that a challenged claim of Bayer's targeted cancer drug sorafenib is invalid due to obviousness, in a win for Israeli pharmaceutical company Teva Pharmaceuticals.
Americas
26 August 2021   Kite Pharma has successfully persuaded the US Court of Appeals for the Federal Circuit to reverse a $1.2 billion win for the Bristol-Meyers Squibb owned Juno Therapeutics over a cancer treatment patent.